Skip to content

Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice

Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice of Extrahepatic Bile Duct: A Multi-center, Prospective, Open-labeled, Real World Study Based on Electronic Data Capture System

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03527875
Enrollment
564
Registered
2018-05-17
Start date
2018-08-31
Completion date
2022-07-31
Last updated
2018-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jaundice, Obstructive, Klatskin Tumor

Brief summary

The purpose of this study is to evaluate the safety and effectiveness of different methods of preoperative biliary drainage in patients with extrahepatic bile duct neoplasms with obstructive jaundice (hilar cholangiocarcinoma, distal bile duct cancer, and periampullary carcinoma), including PTBD (Percutaneous Transhepatic Biliary Drainage), ENBD (Endoscopic Nasobiliary Drainage) and EBS (Endoscopic Biliary Stenting).

Interventions

PROCEDUREPTBD group

Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients

PROCEDUREENBD group

Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients

PROCEDUREEBS group

Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who meet the following four criteria are included into the study: 1. Preoperative clinical diagnosis of hilar cholangiocarcinoma, distal bile duct cancer, periampullary cancer without distant metastasis or peripheral vascular invasion, and plan for radical surgery; 2. Serum total bilirubin is higher than 51 umol/l; 3. Age is older than 18 and younger than 80 years old; 4. Sign in informed consent to receive preoperative PTBD, ENBD, EBS or without PBD.

Exclusion criteria

* If any of the following items are met, the subject cannot enter the study. 1. Incorporate severe mental illness, severe heart, lungs and kidneys disease, etc., and be unable to tolerate surgery; 2. Malignant obstructive jaundice caused by metastatic tumors; 3. Pregnancy or lactation women.

Design outcomes

Primary

MeasureTime frameDescription
Complication rate after drainageFrom PBD to completion of radical surgery, an average of 1 monthComplication rate between PBD (preoperative biliary drainage) and radical surgery
Complication rate after radical surgery1 month post operativelyComplication rate after radical surgery
Success rate of PBDDay 1Success rate of different methods of PBD

Secondary

MeasureTime frameDescription
implantation metastasisDay 1Rate of implantation metastasis
Rate of change in Total bilirubin2 weeks after PBDRecovery efficiency of liver function
operative timeDay 1duration of radical surgery
Rate of change in aspartate aminotransferase2 weeks after PBDRecovery efficiency of liver function
Rate of change in alanine aminotransferase2 weeks after PBDRecovery efficiency of liver function
Hepatoduodenal edemaat time of radical surgeryDegree of hepatoduodenal edema (including no edema, mild edema, moderate edema, and severe edema)
Perioperative mortalityfrom PBD to 4 weeks after surgery, an average of 2 monthMortality between PBD and 4 weeks after surgery

Contacts

Primary ContactHoubao Liu, PHD
houbaoliu@aliyun.com13818971698

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026